Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Metrics: PDF 1046 views | HTML 1493 views | ?
Daniel J. Coleman1, Kathryn Van Hook1, Carly J. King1,2, Jacob Schwartzman1, Robert Lisac1, Joshua Urrutia1, Archana Sehrawat1, Josha Woodward1, Nicholas J. Wang1,2, Roman Gulati3, George V. Thomas1, Tomasz M. Beer1, Martin Gleave4, James E. Korkola1,2, Lina Gao1, Laura M. Heiser1,2, Joshi J. Alumkal1
1OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
2Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A
3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, U.S.A
4The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Joshi J. Alumkal, email: email@example.com
Keywords: genitourinary cancers: prostate, hormone signaling and inhibitors, regulation of gene expression in drug resistance, androgen receptor mutations, BET bromodomain inhibition
Received: January 13, 2016 Accepted: May 07, 2016 Published: June 3, 2016
Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) – the lethal form of the disease that has progressed despite therapies that interfere with activation of androgen receptor (AR) signaling. One emergent resistance mechanism to medical castration is synthesis of intratumoral androgens that activate the AR. This insight led to the development of the AR antagonist enzalutamide. However, resistance to enzalutamide invariably develops, and disease progression is nearly universal. One mechanism of resistance to enzalutamide is an F877L mutation in the AR ligand-binding domain that can convert enzalutamide to an agonist of AR activity. However, mechanisms that contribute to the agonist switch had not been fully clarified, and there were no therapies to block AR F877L. Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR. Further, enzalutamide treatment of AR F877L-expressing cell lines recapitulated the effects of androgen activation of F877L AR or wild-type AR. Because the BET bromodomain inhibitor JQ-1 was previously shown to block androgen activation of wild-type AR, we tested JQ-1 in AR F877L-expressing CRPC models. We determined that JQ-1 suppressed androgen or enzalutamide activation of mutant F877L AR and suppressed growth of mutant F877L AR CRPC tumors in vivo, demonstrating a new strategy to treat tumors harboring this mutation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.